Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Signaturefd LLC

Signaturefd LLC decreased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 24.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,107 shares of the biotechnology company’s stock after selling 2,644 shares during the period. Signaturefd LLC’s holdings in Sarepta Therapeutics were worth $1,012,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Mather Group LLC. purchased a new position in Sarepta Therapeutics during the first quarter worth approximately $28,000. Riggs Asset Managment Co. Inc. boosted its position in shares of Sarepta Therapeutics by 125.0% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 125 shares during the last quarter. Innealta Capital LLC purchased a new stake in shares of Sarepta Therapeutics in the second quarter valued at about $31,000. New Covenant Trust Company N.A. acquired a new stake in Sarepta Therapeutics during the first quarter worth about $32,000. Finally, GAMMA Investing LLC raised its stake in Sarepta Therapeutics by 37.0% during the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 87 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Sarepta Therapeutics

In related news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Michael Andrew Chambers acquired 37,038 shares of the business’s stock in a transaction on Friday, August 16th. The shares were bought at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the acquisition, the director now owns 284,034 shares in the company, valued at $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Piper Sandler dropped their price target on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Needham & Company LLC reissued a “buy” rating and set a $205.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 14th. Barclays decreased their price target on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Cantor Fitzgerald reissued a “neutral” rating and set a $152.00 price objective on shares of Sarepta Therapeutics in a research report on Friday, September 20th. Finally, Jefferies Financial Group initiated coverage on shares of Sarepta Therapeutics in a research report on Monday. They issued a “buy” rating and a $165.00 target price on the stock. Two research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $182.95.

Sarepta Therapeutics Trading Up 1.1 %

SRPT opened at $129.88 on Thursday. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. The stock has a market capitalization of $12.28 billion, a price-to-earnings ratio of 1,180.73 and a beta of 0.82. The business has a fifty day moving average price of $128.87 and a 200 day moving average price of $132.42. Sarepta Therapeutics, Inc. has a 12 month low of $55.25 and a 12 month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The business had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. During the same period in the previous year, the company posted ($0.27) earnings per share. The business’s revenue for the quarter was up 38.9% on a year-over-year basis. Sell-side analysts expect that Sarepta Therapeutics, Inc. will post 1.45 earnings per share for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.